In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease

Experimental Neurology

Volumn 238, Issue 2, 2012, Pages 133-137

  Ridder, Dirk A ^a   Schwaninger, Markus ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Glitazones; MPP+; MPTP; Oxidative stress; PPAR gamma

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; GLITAZONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN ISCHEMIA; CELL ACTIVATION; CELL SURVIVAL; CONGESTIVE HEART FAILURE; DOPAMINERGIC NERVE CELL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; FRACTURE; GENE TARGETING; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT INDICATION; WEIGHT GAIN;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; HUMANS; MALE; PARKINSON DISEASE; PPAR GAMMA;

EID: 84866544305     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.08.012     Document Type: Note

References (61)

1. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4:585-595.
2. Blandini F., Armentero M.T. Animal models of Parkinson's disease. FEBS J. 2012, 279:1156-1166.
3. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
4. Carta A.R., Pisanu A., Carboni E. Do PPAR-gamma agonists have a future in Parkinson's disease therapy?. Parkinsons Dis. 2011, 2011:689181.
5. Caudle W.M., Zhang J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp. Neurol. 2009, 220:230-233.
6. Chaturvedi R.K., Beal M.F. PPAR: a therapeutic target in Parkinson's disease. J. Neurochem. 2008, 106:506-518.
7. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001, 7:48-52.
8. Colca J.R., McDonald W.G., Waldon D.J., Leone J.W., Lull J.M., Bannow C.A., Lund E.T., Mathews W.R. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E252-E260.
9. Collino M., Patel N.S., Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther. Adv. Cardiovasc. Dis. 2008, 2:179-197.
10. Dagda R.K., Zhu J., Chu C.T. Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion 2009, 9:289-298.
11. Decressac M., Mattsson B., Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp. Neurol. 2012, 235:306-315.
12. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 2004, 88:494-501.
13. Doshi L.S., Brahma M.K., Bahirat U.A., Dixit A.V., Nemmani K.V. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin. Investig. Drugs 2010, 19:489-512.
14. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., Dello Russo C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 2005, 70:177-188.
15. Festuccia W.T., Oztezcan S., Laplante M., Berthiaume M., Michel C., Dohgu S., Denis R.G., Brito M.N., Brito N.A., Miller D.S., Banks W.A., Bartness T.J., Richard D., Deshaies Y. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 2008, 149:2121-2130.
16. Ghosh A., Roy A., Liu X., Kordower J.H., Mufson E.J., Hartley D.M., Ghosh S., Mosley R.L., Gendelman H.E., Pahan K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18754-18759.
17. Giannini S., Serio M., Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J. Endocrinol. Invest. 2004, 27:982-991.
18. Gille G., Reichmann H. Iron-dependent functions of mitochondria-relation to neurodegeneration. J. Neural Transm. 2011, 118:349-359.
19. Gupta A., Dawson V.L., Dawson T.M. What causes cell death in Parkinson's disease?. Ann. Neurol. 2008, 64(Suppl. 2):S3-S15.
20. Hsuan S.L., Klintworth H.M., Xia Z. Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. J. Neurosci. 2006, 26:4481-4491.
21. Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.C., Cass W.A., Sullivan P.G., Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 2007, 100:1375-1386.
22. Jung T.W., Lee J.Y., Shim W.S., Kang E.S., Kim S.K., Ahn C.W., Lee H.C., Cha B.S. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J. Neurol. Sci. 2007, 253:53-60.
23. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2005, 191:331-336.
24. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2884-2889.
25. Kotarsky K., Nilsson N.E., Flodgren E., Owman C., Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 2003, 301:406-410.
26. Kulich S.M., Horbinski C., Patel M., Chu C.T. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic. Biol. Med. 2007, 43:372-383.
27. Kung J., Henry R.R. Thiazolidinedione safety. Expert Opin. Drug Saf. 2012, 11:565-579.
28. Laloux C., Petrault M., Lecointe C., Devos D., Bordet R. Differential susceptibility to the PPAR-gamma agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacol. Res. 2012, 65:514-522.
29. Landreth G., Jiang Q., Mandrekar S., Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
30. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10813-10818.
31. Loane D.J., Deighan B.F., Clarke R.M., Griffin R.J., Lynch A.M., Lynch M.A. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol. Aging 2009, 30:920-931.
32. Lu M., Sarruf D.A., Talukdar S., Sharma S., Li P., Bandyopadhyay G., Nalbandian S., Fan W., Gayen J.R., Mahata S.K., Webster N.J., Schwartz M.W., Olefsky J.M. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat. Med. 2011, 17:618-622.
33. Luconi M., Cantini G., Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer?. Steroids 2010, 75:585-594.
34. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martinez A., Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J. Biol. Chem. 2005, 280:21453-21462.
35. Ma D., Tao B., Warashina S., Kotani S., Lu L., Kaplamadzhiev D.B., Mori Y., Tonchev A.B., Yamashima T. Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys. Neurosci. Res. 2007, 58:394-401.
36. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997, 47:29-35.
37. Martin H.L., Mounsey R.B., Mustafa S., Sathe K., Teismann P. Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPARgamma) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp. Neurol. 2012, 235:528-538.
38. Miller B.W., Willett K.C., Desilets A.R. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann. Pharmacother. 2011, 45:1416-1424.
39. Myers M.G., Burant C.F. PPAR-γ action: it's all in your head. Nat. Med. 2011, 17:544-545.
40. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008, 28:9287-9296.
41. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68:1820-1825.
42. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
43. Quinn L.P., Crook B., Hows M.E., Vidgeon-Hart M., Chapman H., Upton N., Medhurst A.D., Virley D.J. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 2008, 154:226-233.
44. Ridder D.A., Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience 2009, 158:995-1006.
45. Romera C., Hurtado O., Mallolas J., Pereira M.P., Morales J.R., Romera A., Serena J., Vivancos J., Nombela F., Lorenzo P., Lizasoain I., Moro M.A. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPAR gamma target gene involved in neuroprotection. J. Cereb. Blood Flow Metab. 2007, 27:1327-1338.
46. Ryan K.K., Li B., Grayson B.E., Matter E.K., Woods S.C., Seeley R.J. A role for central nervous system PPAR-γ in the regulation of energy balance. Nat. Med. 2011, 17:623-626.
47. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 2009, 29:954-963.
48. Smith N.J., Stoddart L.A., Devine N.M., Jenkins L., Milligan G. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J. Biol. Chem. 2009, 284:17527-17539.
49. Sobrado M., Pereira M.P., Ballesteros I., Hurtado O., Fernandez-Lopez D., Pradillo J.M., Caso J.R., Vivancos J., Nombela F., Serena J., Lizasoain I., Moro M.A. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J. Neurosci. 2009, 29:3875-3884.
50. Steneberg P., Rubins N., Bartoov-Shifman R., Walker M.D., Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005, 1:245-258.
51. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28:551-558.
52. Swanson C.R., Joers V., Bondarenko V., Brunner K., Simmons H.A., Ziegler T.E., Kemnitz J.W., Johnson J.A., Emborg M.E. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflammation 2011, 8:91.
53. Ulusoy G.K., Celik T., Kayir H., Gursoy M., Isik A.T., Uzbay T.I. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Res. Bull. 2011, 85:380-384.
54. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:365-375.
55. Xing B., Liu M., Bing G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity. J. Neuroimmunol. 2007, 192:89-98.
56. Xing B., Xin T., Hunter R., Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J. Neuroinflammation 2008, 5:4.
57. Yamashima T. 'PUFA-GPR40-CREB signaling' hypothesis for the adult primate neurogenesis. Prog. Lipid Res. 2012, 51:221-231.
58. Yu H.C., Feng S.F., Chao P.L., Lin A.M. Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system. Neuropathol. Appl. Neurobiol. 2010, 36:612-622.
59. Zhao X., Sun G., Zhang J., Strong R., Song W., Gonzales N., Grotta J.C., Aronowski J. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann. Neurol. 2007, 61:352-362.
60. Zhao X., Strong R., Zhang J., Sun G., Tsien J.Z., Cui Z., Grotta J.C., Aronowski J. Neuronal PPARγ deficiency increases susceptibility to brain damage after cerebral ischemia. J. Neurosci. 2009, 29:6186-6195.
61. Zuris J.A., Harir Y., Conlan A.R., Shvartsman M., Michaeli D., Tamir S., Paddock M.L., Onuchic J.N., Mittler R., Cabantchik Z.I., Jennings P.A., Nechushtai R. Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor protein. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13047-13052.